Vyne Therapeutics Inc
VYNE0.590USD
-0.028-4.45%
Close 03/30, 16:00（ET）Quotes delayed by 15 min
179.69KMarket Cap
LossP/E TTM
More Details of Vyne Therapeutics Inc Company
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Vyne Therapeutics Inc Info
Ticker SymbolVYNE
Company nameVyne Therapeutics Inc
IPO dateJan 25, 2018
CEODomzalski (David)
Number of employees13
Security typeOrdinary Share
Fiscal year-endJan 25
Address685 Route 202/206 N., Suite 301
CityBRIDGEWATER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code08807
Phone18007757936
Websitehttps://vynetherapeutics.com/
Ticker SymbolVYNE
IPO dateJan 25, 2018
CEODomzalski (David)
Company Executives of Vyne Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
104.92K
-7.49%
Ms. Mutya Fonte Harsch, J.D.
Ms. Mutya Fonte Harsch, J.D.
Chief Legal Officer, General Counsel, Secretary
Chief Legal Officer, General Counsel, Secretary
59.24K
+7.59%
Dr. Iain Stuart, Ph.D.
Dr. Iain Stuart, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
49.93K
+11.27%
Mr. Steven L. Basta
Mr. Steven L. Basta
Independent Director
Independent Director
7.45K
--
Ms. Elisabeth A. Sandoval Little
Ms. Elisabeth A. Sandoval Little
Independent Director
Independent Director
--
--
Mr. David Domzalski
Mr. David Domzalski
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Sharon Barbari
Ms. Sharon Barbari
Independent Director
Independent Director
--
--
Mr. Patrick G. Lepore
Mr. Patrick G. Lepore
Lead Independent Director
Lead Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
104.92K
-7.49%
Ms. Mutya Fonte Harsch, J.D.
Ms. Mutya Fonte Harsch, J.D.
Chief Legal Officer, General Counsel, Secretary
Chief Legal Officer, General Counsel, Secretary
59.24K
+7.59%
Dr. Iain Stuart, Ph.D.
Dr. Iain Stuart, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
49.93K
+11.27%
Mr. Steven L. Basta
Mr. Steven L. Basta
Independent Director
Independent Director
7.45K
--
Ms. Elisabeth A. Sandoval Little
Ms. Elisabeth A. Sandoval Little
Independent Director
Independent Director
--
--
Mr. David Domzalski
Mr. David Domzalski
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2024
FY2023
FY2022
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
Royalty revenues
501.00K
0.00%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Royalty revenues
501.00K
0.00%
Shareholding Stats
Updated: Fri, Feb 20
Updated: Fri, Feb 20
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Shay Capital LLC
4.87%
Anson Funds Management LP.
3.82%
Access Industries, Inc.
3.35%
Nantahala Capital Management, LLC
3.00%
T3 Companies, LLC
2.84%
Other
82.11%
Shareholders
Shareholders
Proportion
Shay Capital LLC
4.87%
Anson Funds Management LP.
3.82%
Access Industries, Inc.
3.35%
Nantahala Capital Management, LLC
3.00%
T3 Companies, LLC
2.84%
Other
82.11%
Shareholder Types
Shareholders
Proportion
Hedge Fund
17.21%
Investment Advisor
6.01%
Corporation
3.35%
Investment Advisor/Hedge Fund
3.03%
Individual Investor
1.37%
Research Firm
0.30%
Venture Capital
0.24%
Other
68.49%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
88
4.87M
14.64%
-6.85M
2025Q3
84
8.51M
25.77%
-898.65K
2025Q2
84
9.46M
56.76%
-1.30M
2025Q1
81
9.36M
56.20%
-1.38M
2024Q4
92
9.37M
63.49%
-533.87K
2024Q3
88
8.98M
61.30%
-594.32K
2024Q2
89
9.65M
66.73%
+287.65K
2024Q1
92
9.64M
67.66%
+101.95K
2023Q4
101
10.22M
72.71%
+4.63M
2023Q3
117
471.27K
14.37%
-340.06K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Shay Capital LLC
492.58K
1.48%
+492.58K
--
Sep 30, 2025
Access Industries, Inc.
1.12M
3.35%
--
--
Oct 15, 2025
Delaware Street Capital, L.L.C.
696.47K
2.09%
--
--
Sep 30, 2024
Acadian Asset Management LLC
446.41K
1.34%
+424.00K
+1891.32%
Sep 30, 2025
Two Sigma Investments, LP
277.39K
0.83%
+277.39K
--
Sep 30, 2025
The Vanguard Group, Inc.
190.38K
0.57%
-305.91K
-61.64%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 12, 2021
Merger
4→1
Feb 12, 2021
Merger
4→1
Date
Ex-dividend Date
Type
Ratio
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 12, 2021
Merger
4→1
Feb 12, 2021
Merger
4→1
Feb 12, 2021
Merger
4→1
Feb 12, 2021
Merger
4→1
